C-Reactive Protein Does Not Predict Future Depression Onset in Adolescents: Preliminary Findings from a Longitudinal Study
Journal of Child and Adolescent Psychopharmacology · 2024
DOI: 10.1089/cap.2023.0091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2024. Verfasst von Joshua J Schwartz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: C-Reactive Protein, Depression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.
Themen: Depression
Abstract (Originalsprache)
Introduction
Neuroinflammatory processes have been extensively implicated in the underlying neurobiology of numerous neuropsychiatric disorders. Elevated C-reactive protein (CRP), an indicator of nonspecific inflammation commonly utilized in clinical practice, has been associated with depression in adults. In adolescents, our group previously found CRP to be associated with altered neural reward function but not with mood and anxiety symptoms assessed cross-sectionally. We hypothesized that the distinct CRP findings in adolescent versus adult depression may be due to chronicity, with neuroinflammatory effects on psychiatric disorders gradually accumulating over time. Here, we conducted a longitudinal study to evaluate if CRP levels predicted future onset or progression of depression in adolescents.
Methods
Participants were 53 adolescents (age = 14.74 ± 1.92 years, 35 female), 40 with psychiatric symptoms and 13 healthy controls. At baseline, participants completed semistructured diagnostic evaluations; dimensional assessments for anxiety, depression, anhedonia, and suicidality severity; and bloodwork to quantify CRP levels. Clinical assessments were repeated at longitudinal follow-up after ∼1.5 years. Spearman's correlation between CRP levels and follow-up symptom severity were controlled for body mass index, age, sex, and follow-up interval and considered significant at the two-tailed, Bonferroni-adjusted p < 0.05 level.
Results
After correction for multiple comparisons, no relationships were identified between baseline CRP levels and follow-up symptom severity.
Conclusion
CRP levels were not significantly associated with future psychiatric symptoms in adolescents in this preliminary analysis. This may suggest that CRP is not a useful biomarker for adolescent depression and anxiety. However, future longitudinal studies with larger sample sizes and incorporating additional indicators of neuroinflammation are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.
- The Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, USA.
ORCID-Profile: Joshua J Schwartz, Russell H Tobe
Förderung
- NIMH NIH HHS
Zitieren
APA
Schwartz, J. J., Roske, C., Liu, Q., Tobe, R. H., Ely, B. A., & Gabbay, V. (2024). C-Reactive Protein Does Not Predict Future Depression Onset in Adolescents: Preliminary Findings from a Longitudinal Study. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2023.0091
Vancouver
Schwartz JJ, Roske C, Liu Q, Tobe RH, Ely BA, Gabbay V. C-Reactive Protein Does Not Predict Future Depression Onset in Adolescents: Preliminary Findings from a Longitudinal Study. Journal of Child and Adolescent Psychopharmacology. 2024. doi:10.1089/cap.2023.0091
BibTeX
@article{Schwartz2024,
author = {Schwartz, Joshua J and Roske, Chloe and Liu, Qi and Tobe, Russell H and Ely, Benjamin A and Gabbay, Vilma},
title = {C-Reactive Protein Does Not Predict Future Depression Onset in Adolescents: Preliminary Findings from a Longitudinal Study},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2024},
doi = {10.1089/cap.2023.0091}
}
EUVIMED